Abstract
Background:
To date, there have been no reported trials that directly compare pembrolizumab/carrelizumab monotherapy versus pembrolizumab/carrelizumab and chemotherapy in the first-line treatment setting of advanced/metastatic non-small cell lung cancer (NSCLC). We performed a Bayesian network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of pembrolizumab/carrelizumab versus pembrolizumab/carrelizumab and chemotherapy in previously treated patients with NSCLC.
Methods:
The following search terms would be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on July 20, 2021, as the search algorithm: (pembrolizumab) OR (carrelizumab) OR (programmed death-1) AND (non-small cell lung cancer) OR (NSCLC). All RCTs that reported the outcomes of pembrolizumab/carrelizumab with or without chemotherapy compared with those of pembrolizumab/carrelizumab alone for patients with NSCLC were considered eligible for inclusion in this meta-analysis. The primary outcomes of interest were overall survival, progression-free survival, objective response rate based on the Response Evaluation Criteria in Solid Tumors for complete and partial responses, and treatment-related adverse events including immune-related adverse events. Secondary outcomes included overall survival, progression-free survival, objective response rate, and treatment-related adverse events for the FDA-approved doses.
Conclusions:
The results of our review will be reported strictly following the PRISMA criteria and the review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.
Ethical approval:
As this study is on the basis of published or registered previous studies, ethical approval and informed consent of patients are not required.
Keywords: carrelizumab, meta-analysis, non-small cell lung cancer, pembrolizumab, protocol
1. Introduction
Lung cancer remains the leading cause of cancer death worldwide. Globally, there were an estimated 1.83 million new lung cancer cases and 1.59 million related deaths in 2012. In the United States, there will be an estimated 234,030 new cases of lung cancer in 2018, including 154,050 deaths from the disease.[1,2] Non-small cell lung cancer (NSCLC) accounts for 80% to 90% of primary lung malignancies.[3] NSCLC is most often diagnosed at the metastatic stage, with a 5-year survival rate of between 0% and 5% using traditional chemotherapy-based strategies. Patients with advanced/metastatic NSCLC have a poor prognosis because of limited surgical options and chemotherapy response rates, whether first-line cytotoxic or platinum-containing dual drug regimens or second-line docetaxel, of only 15% to 30%.[4]
Programmed death-1 is a protein expressed on activated T cells and pre-B cells as well as tumor cells, including NSCLC. Inhibition of the programmed death-1 pathway has been shown to restore T cell activity against tumor cells. Immunotherapies involving monoclonal antibodies targeting programmed death-1 (carrezumab and pembromezumab) offer an alternative for patients with NSCLC in second-line therapy.[5–7] Several elegant global trials have shown that anti-programmed cell death 1 or immune checkpoint inhibitors combined with chemotherapy significantly improve progression-free survival and overall survival in advanced non-squamous NSCLC compared with chemotherapy alone, regardless of programmed death-1 expression levels.[8–10]
To date, there have been no reported trials that directly compare pembrolizumab/carrelizumab monotherapy versus pembrolizumab/carrelizumab and chemotherapy in the first-line treatment setting of advanced/metastatic NSCLC. We performed a Bayesian network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of pembrolizumab/carrelizumab versus pembrolizumab/carrelizumab and chemotherapy in previously treated patients with NSCLC.
2. Materials and methods
2.1. Data sources and search strategy
The following search terms would be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on July 20, 2021, as the search algorithm: (pembrolizumab) OR (carrelizumab) OR (programmed death-1) AND (non-small cell lung cancer) OR (NSCLC). Two searchers would independently draft and carry out the search strategy, and the third member would further complete it. No time limit was given to publication date. References within included articles were reviewed to include articles that were not included within our literature search. As this study was on the basis of published or registered studies, ethical approval and informed consent of patients were not required. The systematic review protocol had been registered on Open Science Framework registries. The registration number was 10.17605/OSF.IO/GYDV2. The systematic literature review was structured to adhere to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses), which included requirements deemed essential for the transparent reporting of results. We would update our protocol for any changes in the entire research process if needed.
2.2. Eligibility criteria
All RCTs that reported the outcomes of pembrolizumab/carrelizumab with or without chemotherapy compared with those of pembrolizumab/carrelizumab alone for patients with NSCLC were considered eligible for inclusion in this meta-analysis. Patients with NSCLC were randomly assigned to receive either pembrolizumab/carrelizumab with or without chemotherapy or pembrolizumab/carrelizumab alone. Biomechanical studies, non-randomized cohort studies, in vitro studies, review articles, techniques, case reports, letters to the editor, and editorials were excluded.
2.3. Data extraction
Data extraction methods would follow the approach outlined by the Cochrane Handbook for Systematic Reviews of Interventions. Two independent authors extracted the following descriptive original information from the selected studies: study characteristics, such as author, year of publication, study design; Patient demographic information, such as number of patients, mean age, body mass index, and sex ratio. The primary outcomes of interest were overall survival, progression-free survival, objective response rate based on the Response Evaluation Criteria in Solid Tumors for complete and partial responses, and treatment-related adverse events including immune-related adverse events. Secondary outcomes included overall survival, progression-free survival, objective response rate, and treatment-related adverse events for the FDA-approved doses. If data were missing or could not be extracted directly, we would contact the appropriate author to ensure information integration. If necessary, we would forgo extracting incomplete data.
2.4. Statistical analysis
We used WinBUGS 1.4.3 software (MRC Biostatistics Unit, Cambridge, UK) and NetMetaXL (Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) to conduct a Bayesian network meta-analysis. Network meta-analysis combined data from several different randomized comparisons of different treatments to provide an internally consistent set of estimates, while respecting randomization in each trial. The network meta-analysis was performed within a generalized linear model framework with a link function that specified the relationship between the results and the model coefficients to be estimated. When the outcome was continuous, the likelihood was modeled as normal. When the outcome was the event rate, the likelihood was modeled as Poisson. The random effects model was used for this analysis. Estimation was performed in a Bayesian context using the non-information prior distribution of the parameters. The model was evaluated using the Deviation Information Criterion, a measure that combines model fit and complexity. The analysis was estimated using a Bayesian Markov Chain Monte Carlo model.
2.5. Quality assessment
The Cochrane Risk of Bias tool was used to assess the risk of bias in randomized clinical trials included by 2 independent reviewers. The quality of the randomized clinical trials was assessed using the following 7 items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The Kappa score, which measured agreement between two reviewers, was given as follows: fair, 0.40 to 0.59; good, 0.60 to 0.74; and excellent, 0.75 or more. Any disputes would be resolved by discussion with the third author to reach a final agreement.
3. Discussion
To date, there have been no reported trials that directly compare pembrolizumab/carrelizumab monotherapy versus pembrolizumab/carrelizumab and chemotherapy in the first-line treatment setting of advanced/metastatic NSCLC. We performed a Bayesian network meta-analysis of RCTs to compare the efficacy and safety of pembrolizumab/carrelizumab versus pembrolizumab/carrelizumab and chemotherapy in previously treated patients with NSCLC.
Author contributions
Conceptualization: Xiangkun Qu.
Data curation: Xiaofei Zhang, Hui Qian.
Formal analysis: Xiaofei Zhang, Hui Qian.
Funding acquisition: Yalin Jiang.
Investigation: Xiaofei Zhang, Hui Qian.
Methodology: Xiangkun Qu.
Project administration: Yalin Jiang.
Resources: Yalin Jiang.
Software: Xiangkun Qu.
Supervision: Xiangkun Qu.
Validation: Hui Qian.
Visualization: Hui Qian.
Writing – original draft: Xiaofei Zhang.
Writing – review & editing: Yalin Jiang.
Footnotes
Abbreviations: NSCLC = non-small cell lung cancer, RCTs = randomized controlled trials.
How to cite this article: Zhang X, Qian H, Qu X, Jiang Y. Efficacy and safety of pembrolizumab/carrelizumab, alone or in combination with chemotherapy in treatment of patients with non-small cell lung cancer: a protocol for evidence-based systematic review and Bayesian network meta-analysis. Medicine. 2021;100:29(e26672).
Funding was provided by Key Research and Development Program of Anhui Province (202104j07020052).
The authors report no conflicts of interest.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
References
- [1].Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–28. [DOI] [PubMed] [Google Scholar]
- [2].Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017;152:271–81. [DOI] [PubMed] [Google Scholar]
- [3].Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497–508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Chen R, Tao Y, Xu X, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med 2018;26:155–66. [PubMed] [Google Scholar]
- [5].Garassino MC, Gadgeel S, Esteban E, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:387–97. [DOI] [PubMed] [Google Scholar]
- [6].Borghaei H, Langer CJ, Gadgeel S, et al. 24-month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2019;14:124–9. [DOI] [PubMed] [Google Scholar]
- [7].Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18:895–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med 2021;9:305–14. [DOI] [PubMed] [Google Scholar]
- [9].Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 2019;5:1043–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 2019;7:347–57. [DOI] [PubMed] [Google Scholar]